Organization
Ascendis Pharma
16 clinical trials
1 abstract
Clinical trial
IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, Standard of Care Chemotherapy, or TransCon TLR7/8 Agonist, or in Combination With Pembrolizumab and Standard of Care Chemotherapy, in Adult Participants With Locally Advanced or Metastatic Solid Tumor MalignanciesStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Multicenter, Open-Label, Extension Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone DeficiencyStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
ACcomplisH: A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Prepubertal Children With Achondroplasia Followed by an Open-Label Extension PeriodStatus: Active (not recruiting), Estimated PCD: 2022-09-27
Clinical trial
A Prospective, Non-interventional (NIS), Long-term, Post-Authorisation Safety Study (PASS) of Patients Treated With LonapegsomatropinStatus: Recruiting, Estimated PCD: 2033-03-01
Clinical trial
A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial Evaluating Efficacy and Safety of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Children With Achondroplasia Followed by an Open Label Extension PeriodStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
enliGHten: A Multicenter, Phase 3, Long-Term, Open-Label Trial Investigating Safety and Efficacy of TransCon hGH Administered Once-Weekly in Children With Growth Hormone Deficiency (GHD) Who Have Completed a Prior TransCon hGH Clinical TrialStatus: Completed, Estimated PCD: 2023-02-21
Clinical trial
A Phase 2, Multicenter, Long-Term, Open Label Extension Trial Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children and Adolescents With AchondroplasiaStatus: , Estimated PCD: 2039-01-01
Clinical trial
New InsiGHTS: A Multicenter, Phase 2, Randomized, Open-label, Active-controlled, Parallel Group Clinical Trial to Investigate the Safety, Tolerability, and Efficacy of Different Dose Levels of Once-weekly Lonapegsomatropin Compared to Daily Somatropin in Prepubertal Individuals With Turner SyndromeStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
PaTHway TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With HypoparathyroidismStatus: Active (not recruiting), Estimated PCD: 2022-01-12
Clinical trial
Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor MalignanciesStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
PaTH Forward: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With HypoparathyroidismStatus: Active (not recruiting), Estimated PCD: 2020-03-06
Clinical trial
ACcomplisH China: A Phase 2, Multicenter, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children With AchondroplasiaStatus: Active (not recruiting), Estimated PCD: 2023-03-15
Clinical trial
Expanded Access Program of Palopegteriparatide in Patients With HypoparathyroidismStatus:
Clinical trial
A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial, Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Infants (0 to <2 Years of Age) With Achondroplasia Followed by an Open Label Extension (OLE) PeriodStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
BelieveIT-201: Phase 2, Randomized Open-labeled Trial of TransCon (TC) TLR7/8 Agonist in Combination With Pembrolizumab or With TC IL-2 β/γ, or Pembrolizumab Alone as Neoadjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2025-04-14
Clinical trial
A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children With AchondroplasiaStatus: Not yet recruiting, Estimated PCD: 2025-07-01
Abstract
Phase 1/2 dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Initial results from dose escalation.Org: The Christ Hospital Health Network, Carolina BioOncology Institute, Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, UPMC Hillman Cancer Center, Tasman Oncology Research,